These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
720 related articles for article (PubMed ID: 31771279)
1. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279 [TBL] [Abstract][Full Text] [Related]
2. GC1118, a novel anti-EGFR antibody, has potent KRAS mutation-independent antitumor activity compared with cetuximab in gastric cancer. Park JE; Jin MH; Hur M; Nam AR; Bang JH; Won J; Oh DY; Bang YJ Gastric Cancer; 2019 Sep; 22(5):932-940. PubMed ID: 30815759 [TBL] [Abstract][Full Text] [Related]
3. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487 [TBL] [Abstract][Full Text] [Related]
4. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. E J; Xing J; Gong H; He J; Zhang W Tumour Biol; 2015 Feb; 36(2):1091-7. PubMed ID: 25326806 [TBL] [Abstract][Full Text] [Related]
5. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab. Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938 [TBL] [Abstract][Full Text] [Related]
6. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands. Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721 [TBL] [Abstract][Full Text] [Related]
7. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer. Ye H; Liu Y; Wu K; Luo H; Cui L Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218 [TBL] [Abstract][Full Text] [Related]
8. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372 [TBL] [Abstract][Full Text] [Related]
9. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways. Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734 [TBL] [Abstract][Full Text] [Related]
10. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280 [TBL] [Abstract][Full Text] [Related]
11. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411 [TBL] [Abstract][Full Text] [Related]
12. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633 [TBL] [Abstract][Full Text] [Related]
13. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607 [TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. Ruzzo A; Graziano F; Canestrari E; Magnani M Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793 [TBL] [Abstract][Full Text] [Related]
16. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis. Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137 [TBL] [Abstract][Full Text] [Related]
17. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells. Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218 [TBL] [Abstract][Full Text] [Related]
18. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120 [TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Temraz S; Mukherji D; Shamseddine A Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]